ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,459.10
      1.11%
      US Tech 100
      18,514.00
      1.00%
      Dow Jones
      40,589.34
      1.64%
      Brent Oil
      79.745
      0.00%
      Bitcoin
      68,579.39
      0.98%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Syndax Pharmaceuticals Inc (SNDX) Quote

      Syndax Pharmaceuticals Inc

      Syndax Pharmaceuticals Inc (SNDX)

      NASDAQ
      24.49
      -0.14
      (-0.57%)
      Closed July 27 4:00PM
      Delayed by 15 minutes
      24.49
      0.01
      (0.04%)
      After Hours: 7:01PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      24.49
      Bid
      22.00
      Ask
      25.70
      Volume
      461,403
      24.425 Day's Range 25.07
      11.215 52 Week Range 25.34
      Market Cap
      2.081B
      Previous Close
      24.63
      Open
      24.88
      Last Trade
      1
      @
      24.43
      Last Trade Time
      Financial Volume
      $ 11,375,501
      VWAP
      24.6542
      Average Volume (3m)
      1,009,158
      Shares Outstanding
      84,987,060
      Dividend Yield
      -
      PE Ratio
      -9.94
      Earnings Per Share (EPS)
      -2.46
      Revenue
      -
      Net Profit
      -209.36M

      About Syndax Pharmaceuticals Inc

      Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.syndax.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Syndax Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SNDX. The last closing price for Syndax Pharmaceuticals was $24.63. Over the last year, Syndax Pharmaceuticals shares have traded in a share price range of $ 11.215 to $ 25.34.

      Syndax Pharmaceuticals currently has 84,987,060 shares outstanding. The market capitalization of Syndax Pharmaceuticals is $2.09 billion. Syndax Pharmaceuticals has a price to earnings ratio (PE ratio) of -9.94.

      SNDX Latest News

      More News

      Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024

      Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass., July 25, 2024 WALTHAM, Mass., July 25, 2024...

      July 25 2024
      PR Newswire (US)

      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., July 5, 2024 WALTHAM, Mass., July 5, 2024 /PRNewswire/ -- Syndax...

      July 05 2024
      PR Newswire (US)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 17 2024
      Edgar (US Regulatory)

      Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

      Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress PR Newswire WALTHAM, Mass...

      June 14 2024
      PR Newswire (US)

      Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

      BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...

      June 10 2024
      GlobeNewswire Inc.

      Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

      Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC PR Newswire WALTHAM, Mass., June 6, 2024 – IDMC recommendation...

      June 06 2024
      PR Newswire (US)

      Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference

      Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire WALTHAM, Mass., June 5, 2024 WALTHAM, Mass., June 5, 2024 /PRNewswire/ -- Syndax...

      June 05 2024
      PR Newswire (US)

      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., June 3, 2024 WALTHAM, Mass., June 3, 2024 /PRNewswire/ -- Syndax...

      June 03 2024
      PR Newswire (US)

      Form 4 - Statement of changes in beneficial ownership of securities

      May 16 2024
      Edgar (US Regulatory)

      Form 3 - Initial statement of beneficial ownership of securities

      May 16 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      11.225.2428018908523.2725.0722.8876260523.80490839CS
      44.120.107896027520.3925.0719.69592963022.992399CS
      122.19.3791871371122.3925.0718.65100915821.0570604CS
      264.5222.633950926419.9725.3418.65106638121.82814696CS
      522.7212.494258153421.7725.3411.215131933518.58931828CS
      15610.1470.662020905914.3529.8611.21589678819.65041687CS
      26015.75180.2059496578.7429.865.3573655519.09531759CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WINTWindtree Therapeutics Inc
      $ 8.24
      (150.46%)
      		48.57M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NBSTWNewbury Street Acquisition Corporation
      $ 0.1349
      (92.71%)
      		122.1k
      YIBOPlanet Image International Ltd
      $ 2.915
      (53.43%)
      		260.07k
      CREVCarbon Revolution Public Ltd
      $ 9.00
      (45.87%)
      		8.06M
      NMHINatures Miracle Holding Inc
      $ 0.2035
      (-48.06%)
      		7.69M
      TANHTantech Holdings Ltd
      $ 0.2585
      (-47.23%)
      		6.75M
      DXCMDexCom Inc
      $ 64.00
      (-40.66%)
      		53.92M
      PSIGPS International Group Ltd
      $ 1.42
      (-31.40%)
      		716.26k
      POAIPredictive Oncology Inc
      $ 1.36
      (-27.27%)
      		6.02M
      SLNASelina Hospitality PLC
      $ 0.0305
      (-18.88%)
      		408.61M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NVDANVIDIA Corporation
      $ 113.06
      (0.69%)
      		293.33M
      SQQQProShares UltraPro Short QQQ
      $ 9.10
      (-2.88%)
      		176.49M
      SGMOSangamo Therapeutics Inc
      $ 0.8612
      (28.15%)
      		123.71M

      SNDX Discussion

      View Posts
      dinogreeves dinogreeves 10 months ago
      SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.
      👍️0
      dinogreeves dinogreeves 10 months ago
      Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.
      👍️0
      dealerschool2006 dealerschool2006 3 years ago
      Nice rebound today for $SNDX, beat the street and conference call was successful!!!
      👍️0
      dealerschool2006 dealerschool2006 3 years ago
      SNDX recovering from panic sale!!!
      👍️0
      dealerschool2006 dealerschool2006 3 years ago
      Panic sale for SNDX on positive results...May options wide swings...
      👍️0
      DaytraderJohn DaytraderJohn 4 years ago
      Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

      They have no product revenue.

      I expect shares to be diluted after earnings.

      Read their 10k. I guess it's a gamble play incase one day they do get approval.
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX looks like this run is going to continue. Let’s hit $15.00 this week folks
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $SNDX Video Chart 01-31-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX next week is going to be fun
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX Hope you guys went all in here...Have a great weekend see y’all on Monday
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX holding this baby!
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX keep climbing baby! Going be going up all next week
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX looking awesome from my call at $8.00
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX got us a runner folks!!!
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX Chomp Chomp Chomp!
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX Weeeeeeeeeee
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      Going to run folks.
      👍️0
      BoilerRoom BoilerRoom 4 years ago
      $SNDX in at $8.00
      👍️0
      TheFinalCD TheFinalCD 4 years ago
      News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...
      👍️0
      whytestocks whytestocks 5 years ago
      News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

      WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

      Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX 3Q18 results—cash=$89.6M:

      https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html
      👍️0
      Spartak Spartak 6 years ago
      Well, the company is done. What a disaster.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

      https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

      The trial continues to test for statsig OS every six months until Nov 2019.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX upgrades BoD:

      https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      #msg-143766395
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

      https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      #msg-143642544
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX 2Q18 CC transcript:

      https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX 2Q18 items—6/30/18 cash=$98.4M…

      PR:
      http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

      CC slides:
      http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153
      👍️0
      Spartak Spartak 6 years ago
      When does pounding stop? Someone hummers it pretty badly.
      👍️0
      fsantes fsantes 6 years ago
      Ill keep a look out for some then!... I’ve been looking as well. Thank you!
      👍️0
      DewDiligence DewDiligence 6 years ago
      No. I generally post anything that's material.
      👍️0
      fsantes fsantes 6 years ago
      Have you heard any new news on SNDX?
      👍️0
      fsantes fsantes 6 years ago
      I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of what’s going on on it
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX requested that the SEC keep this document in redacted form:

      https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

      This was filed as an exhibit to the most recent 10-Q.
      👍️0
      fsantes fsantes 6 years ago
      Do you know what’s the news that came out about? When I look it’s blank..
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX, NKTR ink clinical-trial collaboration for Entinostat + NK-214 in second-lime melanoma:

      https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

      NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX ENCORE-601 update…

      PR:
      https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-300650233.html

      CC slides:
      http://ir.syndax.com/static-files/7c0c8627-0b81-43d6-9210-6cb02684db5f
      👍️0
      tika1 tika1 6 years ago
      After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

      All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.
      👍️0
      DewDiligence DewDiligence 6 years ago
      Transcript of SNDX 1Q18 CC:

      https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-235620976.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX new investor slide set:

      http://ir.syndax.com/static-files/da19e99b-2bd2-4456-91fe-0e67b97fc0d0
      👍️0
      DewDiligence DewDiligence 6 years ago
      The 1Q18 10-Q has been filed:

      https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-10q_20180331.htm
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX 1Q18 results—cash=$113M:

      https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical-and-business-update-300644832.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX ASCO lineup:

      https://finance.yahoo.com/news/syndax-pharmaceuticals-announces-presentations-2018-200500073.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      Yes—please see my reply in #msg-140012720.
      👍️0
      tika1 tika1 6 years ago
      Dew,
      Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness?


      Oral Presentations:

      Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
      Presenter: Anthony W. Tolcher, M.D.
      Category: Clinical Trials
      Session: Biomarkers in Immuno-oncology
      Abstract Number: CT179
      Location: N Hall C - McCormick Place North (Level 1)
      Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX presentation lineup at AACR:

      https://finance.yahoo.com/news/syndax-present-2018-american-association-110000742.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      The annual-report proxy has been filed:

      https://www.sec.gov/Archives/edgar/data/1395937/000114036118018005/bp05609x1_proxy.htm
      👍️0
      DewDiligence DewDiligence 6 years ago
      The 2017 10-K has been filed:

      https://www.sec.gov/Archives/edgar/data/1395937/000156459018004911/sndx-10k_20171231.htm
      👍️0

      Your Recent History

      NASDAQ
      SNDX
      Syndax Pharmaceuticals
      BIT
      S27876
      Societe Generale Effekten
      LSE
      GSK
      Gsk
      Delayed Upgrade Clock